Company: NCNA
Filing Date: 2025-03-20
Form Type: 20-F
Source: 0000950170-25-042709
Chunk: 85

Company: NuCana plc
Filing Date: 2025-03-20
Form: 20-F
Item: Item 3
Chunk 85
---
 of our clinical trial subjects, in our data centers and on our networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Although to our knowledge we have not experienced any such material cybersecurity incident to date, any such incident could compromise our networks and the information stored there could be accessed, publicly disclosed, modified, disrupted, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, regulatory penalties, disrupt our operations, damage our reputation, and cause a loss of confidence in us and our ability to conduct clinical trials and our competitive advantage, which could adversely affect our reputation and delay the clinical development of our product candidates.
 Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
 The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:
 •others may be able to make, use or sell compounds that are similar to our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed;
 •we, our licensors or strategic partners might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;
 •we, our licensors or strategic partners, or future licensors or strategic partners might not have been the first to file patent applications covering certain of our inventions;
 •others may independently develop similar or alternative technologies, or duplicate any of our technologies without infringing our intellectual property rights;
 •it is possible that our pending patent applications will not lead to issued patents;
 •issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges by our competitors;
 •our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;
 •we may not develop additional proprietary technologies that are patentable; and
 •the patents of others may have an adverse effect on our business.
 

Risks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business
 We currently